Business Wire

Biognosys Presenting Data on its TrueDiscovery™ and TrueTarget™ Proteomics Platforms at the AACR Annual Meeting 2022


Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the details of its presence at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held April 8-13, 2022, both in person in New Orleans, US and virtually. The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery™ and TrueTarget™. Additionally, Biognosys contributed to a poster that will be presented by its collaborator, NeoGenomics.

“The proteome contains a wealth of information about health and disease, and mass spectrometry-based proteomics has great potential in uncovering that information,” commented Lukas Reiter, Ph.D., Chief Technology Officer at Biognosys. “Our AACR data shows how Biognosys has been able to establish mass spectrometry-based proteomics technology to provide detailed and unbiased insights about the proteome. We illustrate how we’ve been able to increase efficiency and scalability at every step of the process. Moreover, we’re showcasing data we’ve generated with our collaborators that demonstrate the practical application of our platforms across all stages of research and drug development, from discovery to clinical settings.”

Biognosys will also be present with a team of scientific experts at booth #885.

Talk Details

  • Abstract 2136: Prediction of small molecule-protein binding events for BRD4 and EGFR inhibitors using HR-LiP, a novel structural proteomics approach
    • Presenter: Yuehan Feng, Ph.D.
    • Collaborator: Cedilla Therapeutics
    • Platform, Technology and Application: TrueTarget, High Resolution Limited Proteolysis Mass Spectrometry (HR-LiP), Drug Target Validation
    • Session: Drug Design and Lead Optimization Strategies Toward Novel or Difficult-to-Drug Cancer Targets
    • Date and Time: Monday, April 11, 3:20 p.m. - 3:35 p.m. CDT

Poster Presentation Details

  • Abstract 1374: Discovery of MHC class I and class II neoantigens in lung cancer in needle biopsy tissue samples using an optimized high-throughput workflow
    • Presenter: Marco Tognetti, Ph.D.
    • Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Immunopeptidome Profiling
    • Session: Tumor Antigens, Antigen Presentation, and Tumor Immunity
    • Date and Time: Monday, April 11, 9:00 a.m. - 12:30 p.m. CDT
  • Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon targeted therapy treatment using deep phosphoproteomic analysis
    • Presenter: Yuehan Feng, Ph.D.
    • Collaborator: Crown Bioscience
    • Platform, Technology, and Application: TrueDiscovery, Hyper Reaction Monitoring, Phosphoproteome Profiling
    • Session: Patient-Derived Xenografts
    • Date and Time: Tuesday, April 12, 1:30 p.m. - 5:00 p.m. CDT
  • Abstract 2924: Target identification, selectivity profiling and mechanistic insights of a CDK9 inhibitor using complementary proteomics methods
    • Presenter: Yuehan Feng, Ph.D.
    • Collaborator: AstraZeneca plc
    • Platform, Technology and Application: TrueTarget, Limited Proteolysis Mass Spectrometry (LiP-MS), Drug Target Deconvolution
    • Session: Structural and Chemical Biology
    • Date and Time: Tuesday, April 12, 9:00 a.m. - 12:30 p.m. CDT
  • Abstract 3923: Ubiquitin ligases implicated as predictive biomarkers for poor outcome to immunotherapy in melanoma patients
    • Presenter: Jakob Vowinckel, Ph.D.
    • Collaborator: NeoGenomics Laboratories
    • Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
    • Session: Proteomics, Signaling Networks, and Biomarker Discovery
    • Date and Time: Wednesday, April 13, 9:00 a.m. - 12:30 p.m. CDT
  • Abstract 3920: Precise solid tumor classification through unbiased quantification of proteoforms deep into tissue leakage
    • Presenter: Marco Tognetti, Ph.D.
    • Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Biofluid Biomarker Discovery
    • Session: Proteomics, Signaling Networks, and Biomarker Discovery
    • Date and Time: Wednesday, April 13, 9:00 a.m. - 12:30 p.m. CDT

NeoGenomics Poster Collaboration Details

  • Abstract 1267: Dual approach using unbiased proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients
    • NeoGenomics Presenter: Anna Juncker-Jensen, Ph.D.
    • Biognosys co-authors: Nigel Beaton, Ph.D.; Kristina Beeler, Ph.D. Tobias Treiber, Ph.D.; Jakob Vowinckel, Ph.D.
    • Platform, Technology and Application: TrueDiscovery, Hyper Reaction Monitoring, Tissue Biomarker Discovery
    • Session: Biomarkers Predictive of Therapeutic Benefit 2
    • Date and Time: Monday, April 11, 9:00 a.m. - 12:30 p.m. CDT

For the most up to date information and resources about Biognosys’ presence at AACR, visit

About TrueDiscovery™

The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.

TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.

TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit

About TrueTarget™

The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.

TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys.

TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification. The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dental Monitoring Launches the Virtual Practice Platform for a Comprehensive, Life-Long Patient Experience18.5.2022 22:10:00 CEST | Press release

Dental Monitoring, the industry-leading company that pioneered the field of intelligent orthodontics, launches the Virtual Practice Platform for a comprehensive, life-long patient experience. This press release features multimedia. View the full release here: More information: (Photo: Business Wire) This groundbreaking Virtual Practice Platform is designed for doctors and patients to partner along the entire treatment journey through a suite of intelligent workflows and tools. By using the platform, doctors will be able to identify, engage, qualify, and convert leads, optimize treatment and monitor patients, as well as benefit from opportunities for new revenue streams. Dental Monitoring is launching the Virtual Practice Platform as the increasing need for remote and intelligent care in the dental industry meets growing patient expectations. Through the platform, the SaaS company aims to spearhead widespread transformation for p

Align Announces Additional Leadership for UK and EMEA to Support Continued Growth18.5.2022 17:11:00 CEST | Press release

Align, the premier global provider of technology infrastructure solutions celebrates significant growth throughout the UK and EMEA markets with management changes to support increasing demand. The appointment of Giulia Marcolina as Managing Director and Mike Konold as AV Solutions Director of Align’s UK-based headquarters, will enable the team to deliver innovative collaborative technology and state-of-the-art AV solutions. This press release features multimedia. View the full release here: Giulia Marcolina, a 15 year veteran with Align, is named Managing Director of Align's UK-based headquarters. (Photo: Business Wire) Giulia brings over 25 years of IT experience, previously serving as Align’s Programme Manager, delivering corporate office relocation and consolidation projects for clients such as Blackrock, Total Gas and Power, and UBS. In her new role, she will lead Align’s team of project managers in building upon Align’s lon

RMS Advances Climate Risk Modeling and Moves More Models to High Definition18.5.2022 16:30:00 CEST | Press release

RMS®, a Moody’s Analytics company and world-leading risk modeling and solutions company, today announces it will be releasing four new High Definition™ (HD) models, including Europe Windstorm, North America Winterstorm (WT), North America Severe Convective Storm (SCS), and Terrorism. RMS HD Models represent the next generation of risk modeling, delivering deeper analysis and granularity from Moody’s. The HD probabilistic models incorporate a high-fidelity, simulation-based framework for modeling event frequency and severity, to provide a major step forward in the quality of catastrophe risk quantification. The framework allows for event footprints to be represented more realistically across larger event sets. The new RMS Europe Windstorm HD Model further enhances the current model and will cover 17 countries, adding Finland and Lichtenstein. The HD model includes a climate variability view and has expanded storm surge analytics to include the U.K., Ireland, France, and Belgium. Storm c

Suketu Upadhyay Elected to Vertex Board of Directors18.5.2022 16:30:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyayhas been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. “We are delighted to have Suky join the Vertex Board. His extensive financial and strategic experience in health care, paired with his leadership and expertise across biopharma and medtech, make him a valuable addition to our board of directors,” said Reshma Kewalramani, M.D., Vertex’s Chief Executive Officer and President. “It’s an honor to join Vertex, a company focused on serial innovation with an

Armory Makes Continuous Deployment Achievable and Effortless, at any Scale, for all Developers18.5.2022 16:17:00 CEST | Press release

Armory, the Continuous Deployment company empowering development teams to easily, reliably, safely, and continuously deploy software at any scale, today announced public early access to their new Continuous Deployment-as-a-Service product. Armory Continuous Deployment-as-a-Service delivers declarative deployments, across multiple environments, that support advanced strategies, so developers can focus on building great code rather than deploying it. “We believe deploying software continuously, at any scale, should be achievable and effortless for all developers of the world, not just the likes of Google and Netflix,” said Jim Douglas, President and CEO, Armory. “It’s our vision and mission to unlock innovation through software to make software continuous, scalable, secure, and safe, so developers can improve and protect their customers’ experience with confidence and ease.” To effectively compete in a software-defined world, development teams must ensure a stellar customer experience. S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom